Published in P T on November 01, 2013
TRIal For Efficacy of Capre on hyperTriglyceridemiA (TRIFECTA) | NCT01455844
Effect of dietary Fatty acids on human lipoprotein metabolism: a comprehensive update. Nutrients (2015) 0.82
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Ethyl-Ester Omega-3 Fatty Acid in Taiwanese Hypertriglyceridemic Patients. J Atheroscler Thromb (2016) 0.81
Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products. Am J Cardiovasc Drugs (2016) 0.79
The Pattern of Fatty Acids Displaced by EPA and DHA Following 12 Months Supplementation Varies between Blood Cell and Plasma Fractions. Nutrients (2015) 0.79
Comparative Studies on the Characteristic Fatty Acid Profiles of Four Different Chinese Medicinal Sargassum Seaweeds by GC-MS and Chemometrics. Mar Drugs (2016) 0.78
Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus. Diabetes Metab Syndr Obes (2016) 0.78
B Cell Activity Is Impaired in Human and Mouse Obesity and Is Responsive to an Essential Fatty Acid upon Murine Influenza Infection. J Immunol (2017) 0.77
n-3 PUFA induce microvascular protective changes during ischemia/reperfusion. Lipids (2014) 0.77
A Comparative Overview of Prescription Omega-3 Fatty Acid Products. P T (2015) 0.75
Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA). Lipids Health Dis (2017) 0.75
Update on the management of severe hypertriglyceridemia--focus on free fatty acid forms of omega-3. Drug Des Devel Ther (2015) 0.75
Switching statin-treated patients from fenofibrate to the prescription omega-3 therapy icosapent ethyl: a retrospective case series. Drugs Ther Perspect (2016) 0.75
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation (2002) 76.93
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 23.07
Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med (2011) 15.30
Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 10.02
Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet (2007) 9.56
Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA (2012) 9.37
Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation (2002) 9.02
n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med (2010) 7.58
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med (2001) 7.51
Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation (2011) 6.36
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med (2012) 6.16
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J (2013) 4.87
OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation (2010) 4.60
The Omega-3 Index: a new risk factor for death from coronary heart disease? Prev Med (2004) 3.52
Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol (2012) 3.23
Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr (2000) 2.92
Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol (2009) 2.83
n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr (1997) 2.71
Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis (2006) 2.56
Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2012) 2.49
Safety considerations with omega-3 fatty acid therapy. Am J Cardiol (2006) 2.17
Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med (2009) 2.17
Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. J Clin Lipidol (2011) 2.00
Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ (2010) 1.89
Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther (2007) 1.86
Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr (2000) 1.77
Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol (2003) 1.76
Metabolic effects of krill oil are essentially similar to those of fish oil but at lower dose of EPA and DHA, in healthy volunteers. Lipids (2010) 1.70
Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Des Devel Ther (2011) 1.68
Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am J Clin Nutr (2002) 1.62
Long chain omega-3 fatty acids and cardiovascular disease: a systematic review. Br J Nutr (2012) 1.60
Krill oil supplementation increases plasma concentrations of eicosapentaenoic and docosahexaenoic acids in overweight and obese men and women. Nutr Res (2009) 1.55
Managing abnormal blood lipids: a collaborative approach. Circulation (2005) 1.44
Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk (1999) 1.40
Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep (2011) 1.31
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res (2008) 1.27
Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. Am J Clin Nutr (1997) 1.25
Evaluation of the effects of Neptune Krill Oil on the clinical course of hyperlipidemia. Altern Med Rev (2004) 1.24
Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther (2008) 1.20
The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans. Am J Clin Nutr (2002) 1.15
n-3 fatty acids, ventricular arrhythmia-related events, and fatal myocardial infarction in postmyocardial infarction patients with diabetes. Diabetes Care (2011) 1.14
Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis (1999) 1.14
Dietary sources of omega 3 fatty acids: public health risks and benefits. Br J Nutr (2012) 1.03
Dietary alpha-linolenic acid, EPA, and DHA have differential effects on LDL fatty acid composition but similar effects on serum lipid profiles in normolipidemic humans. J Nutr (2009) 1.02
Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia. J Clin Lipidol (2009) 1.02
Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. Diabetes Care (2007) 1.01
The cost-effectiveness of omega-3 supplements for prevention of secondary coronary events. Manag Care (2006) 0.99
A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). Clin Ther (2013) 0.97
Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial. Pharmacoeconomics (2001) 0.95
The science behind dietary omega-3 fatty acids. CMAJ (2008) 0.94
Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. J Am Soc Nephrol (1999) 0.93
Absorption of the n-3 eicosapentaenoic and docosahexaenoic acids as ethyl esters and triglycerides by humans. Am J Clin Nutr (1991) 0.91
The enteral bioavailability of eicosapentaenoic acid and docosahexaenoic acid is as good from ethyl esters as from glyceryl esters in spite of lower hydrolytic rates by pancreatic lipase in vitro. Biochim Biophys Acta (1993) 0.89
Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized double-blind (ORD) study. J Clin Lipidol (2013) 0.89
Krill oil. Monograph. Altern Med Rev (2010) 0.85
Comparative effects of prolonged intake of highly purified fish oils as ethyl ester or triglyceride on lipids, haemostasis and platelet function in normolipaemic men. Eur J Clin Nutr (1993) 0.85
Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg/dL in patients with severe hypertriglyceridemia. J Clin Lipidol (2012) 0.85
Long chain omega-3 dietary supplements: a review of the National Library of Medicine Herbal Supplement Database. Metab Syndr Relat Disord (2011) 0.82
Differences between dietary supplement and prescription drug omega-3 fatty acid formulations: a legislative and regulatory perspective. J Am Coll Nutr (2008) 0.82
Cardiovascular effects of B-vitamins and/or N-3 fatty acids: the SU.FOL.OM3 trial. Int J Cardiol (2012) 0.80
Novel developments in omega-3 fatty acid-based strategies. Curr Opin Lipidol (2011) 0.79
Differentiating prescription omega-3-acid ethyl esters (P-OM3) from dietary-supplement omega-3 fatty acids. Curr Med Res Opin (2007) 0.79
Patient characteristics and medical care costs associated with hypertriglyceridemia. Am J Cardiol (2011) 0.78
Hospital use and medical care costs up to 5 years after triglyceride lowering among patients with severe hypertriglyceridemia. J Clin Lipidol (2012) 0.78
Cost-effectiveness of highly purified omega-3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: results of Markov modelling in a UK setting. Eur J Heart Fail (2011) 0.78
Eicosapentaenoic acid effect on hyperlipidemia in menopausal Japanese women. The Niigata Epadel Study Group. Obstet Gynecol (2000) 0.78
Omega-3 oil: fish or pills? Consum Rep (2003) 0.76
Intensive smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular disease. Chest (2007) 2.90
Analysis of healthcare resource utilization with intensive insulin therapy in critically ill patients. Crit Care Med (2006) 2.21
Academic pharmacy administrators' perceptions of core requirements for entry into professional pharmacy programs. Am J Pharm Educ (2008) 2.19
Nebulized opioids use in COPD. Chest (2004) 1.60
Amiodarone versus sotalol for the treatment of atrial fibrillation after open heart surgery: the Reduction in Postoperative Cardiovascular Arrhythmic Events (REDUCE) trial. Am Heart J (2004) 1.49
Economic evaluation of a disease management program for chronic obstructive pulmonary disease. COPD (2011) 1.49
Antiplatelet drug resistance: not ready for prime time. Pharmacotherapy (2005) 1.45
An efficiency evaluation of protocols for tight glycemic control in intensive care units. Am J Crit Care (2007) 1.05
Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am Heart J (2003) 1.03
The economic impact of chronic obstructive pulmonary disease. Expert Opin Pharmacother (2002) 0.99
Pharmacologic prophylaxis of postoperative atrial fibrillation in patients undergoing cardiac surgery: beyond beta-blockers. Pharmacotherapy (2010) 0.89
Novel strategies for managing dyslipidemia: treatment beyond statins. Postgrad Med (2012) 0.86
Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: meta-analysis of dose response and timing of initiation. Pharmacotherapy (2007) 0.85
National Pharmacy Cardiovascular Council treatment guidelines for the management of type 2 diabetes mellitus: toward better patient outcomes and new roles for pharmacists. Pharmacotherapy (2002) 0.85
Comparison of amlodipine/valsartan fixed-dose combination therapy and conventional therapy. Manag Care (2010) 0.84
Reteplase: a review of its use in the management of thrombotic occlusive disorders. Am J Cardiovasc Drugs (2006) 0.82
Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid. Expert Opin Pharmacother (2010) 0.82
Spotlight on reteplase in thrombotic occlusive disorders. BioDrugs (2007) 0.81
Intravenous labetalol compared with intravenous nicardipine in the management of hypertension in critically ill patients. J Crit Care (2012) 0.81
Reducing the risk of obesity: defining the role of weight loss drugs. Pharmacotherapy (2013) 0.80
Effect of omega-3 fatty acid supplementation on the arachidonic acid:eicosapentaenoic acid ratio. Pharmacotherapy (2007) 0.80
An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol. Cardiovasc Ther (2014) 0.79
Pharmacoeconomic evaluation of COPD. 2000. Chest (2009) 0.79
Impact of renal dysfunction on the prognostic value of the TIMI risk score in patients with non-ST elevation acute coronary syndrome. Coron Artery Dis (2011) 0.78
Pharmacologic treatment of chronic obstructive pulmonary disease: past, present, and future. Pharmacotherapy (2003) 0.78
A systematic review of nicardipine vs labetalol for the management of hypertensive crises. Am J Emerg Med (2011) 0.78
National survey of pharmacists about coronary heart disease, hypercholesterolemia, nonprescription statintherapy, and pharmacists' services. J Am Pharm Assoc (2003) (2004) 0.77
Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease. Pharmacotherapy (2002) 0.76
Creating a path to the summit by thinking off the map: report of the 2008-2009 Academic Affairs Committee. Am J Pharm Educ (2009) 0.76
Impact of nesiritide on health care resource utilization and complications in patients with decompensated heart failure. Pharmacotherapy (2004) 0.76
Randomized, double-blind, crossover comparison of amlodipine and valsartan in african-americans with hypertension using 24-hour ambulatory blood pressure monitoring. Pharmacotherapy (2006) 0.76
Report of the 2009-2010 standing committee on advocacy. Am J Pharm Educ (2010) 0.75
Pharmacist compensation for cognitive services: focus on the physician office and community pharmacy. Pharmacotherapy (2004) 0.75
Nesiritide for heart failure: impact on costs and complications. Expert Rev Pharmacoecon Outcomes Res (2005) 0.75
Fingernail clubbing and chromonychia associated with the use of angiotensin II receptor blockers. Pharmacotherapy (2004) 0.75
Prevalence, treatment, and control of hypertension in residents of skilled nursing facilities. Consult Pharm (2008) 0.75
Role of dronedarone in atrial fibrillation: more questions than answers. Pharmacotherapy (2010) 0.75
Low high-density lipoprotein cholesterol is associated with impaired endothelial function in Asian Indians. Ethn Dis (2005) 0.75
Pharmacoeconomic considerations with statin therapy. Expert Opin Pharmacother (2006) 0.75
Impact of ranolazine on clinical outcomes and healthcare resource utilization in patients with refractory angina pectoris. Am J Cardiovasc Drugs (2013) 0.75